Millipore Sigma Vibrant Logo

AB761 Anti-Collagen Type II Antibody

View Products on Sigmaaldrich.com
AB761
500 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HELISA, WB, ICC, IHCRbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue NumberAB761
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Collagen Type II Antibody
      References
      Product Information
      FormatAffinity Purified
      HS Code3002 15 90
      PresentationRabbit antiserum passed over agarose sorbents with immobilized human blood plasma proteins and human collagen types I, III, IV and V. Antibody was affinity purified on immobilized human collagen type II.

      Product is liquid in 0.15M sodium chloride, 10mM sodium phosphate pH 7.5 with 0.1% mannitol and 0.1% dextran as stabilizers. No preservative.
      Quality LevelMQ100
      Applications
      ApplicationAnti-Collagen Type II Antibody detects level of Collagen Type II & has been published & validated for use in ELISA, WB, IC, IH.
      Key Applications
      • ELISA
      • Western Blotting
      • Immunocytochemistry
      • Immunohistochemistry
      Application NotesELISA 1:1000.

      Indirect immunofluorescence on cryostat sections or cultured cells 1:10-1:20

      Western Blot 1:100

      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenCollagen type II extracted and purified from human cartilage.
      HostRabbit
      SpecificityThe antibody reacts with both native and denatured human collagen type II.



      Cross Reactivity Percent

      Human collagen type II 90%

      Human collagen type I, III, IV, V < 1%

      Human plasma proteins do not interfere with binding to collagen.
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen found in cartilage and the vitreous humor of the eye. Mutations in this gene are associated with achondrogenesis, chondrodysplasia, early onset familial osteoarthritis, SED congenita, Langer-Saldino achondrogenesis, Kniest dysplasia, Stickler syndrome type I, and spondyloepimetaphyseal dysplasia Strudwick type. In addition, defects in processing chondrocalcin, a calcium binding protein that is the C-propeptide of this collagen molecule, are also associated with chondrodysplasia. There are two transcripts identified for this gene.
      Gene Symbol
      • COL2A1
      • SEDC
      • COL11A3
      • ANFH
      • MGC131516
      • chondrocalcin
      • AOM
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02458 # Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.
      SIZE: 1487 amino acids; 141785 Da
      SUBUNIT: Homotrimers of alpha 1(II) chains.
      SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
      TISSUE SPECIFICITY: High expression of isoform 2 in juvenile chondrocyte and low in fetal chondrocyte.
      PTM: Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & The N-telopeptide is covalently linked to the helical COL2 region of alpha 1(IX), alpha 2(IX) and alpha 3(IX) chain. The C- telopeptide is covalently linked to an another site in the helical region of alpha 3(IX) COL2.
      DISEASE: SwissProt: P02458 # Defects in COL2A1 are the cause of a variety of chondrodysplasia including hypochondrogenesis and osteoarthritis. & Defects in COL2A1 are the cause of spondyloepiphyseal dysplasia congenital type (SEDC) [MIM:183900]. This disorder is characterized by disproportionate short stature and pleiotropic involvement of the skeletal and ocular systems. & Defects in COL2A1 are the cause of Strudwick type spondyloepimetaphyseal dysplasia (SEMD) [MIM:184250]. SEMD is characterized by disproportionate short stature, pectus carinatum, and scoliosis, as well as dappled metaphyses (which is not seen in SEDC). & Defects in COL2A1 are the cause of achondrogenesis hypochondrogenesis type 2 (ACG2) [MIM:200610]. ACG2 is a disease characterized by the absence of ossification in the vertebral column, sacrum and pubic bones. & Defects in COL2A1 are the cause of Legg-Calve-Perthes disease (LCPD) [MIM:150600]; also known as Legg-Perthes disease or Perthes disease. LCPD is characterized by loss of circulation to the femoral head, resulting in avascular necrosis in a growing child. Clinical pictures of the disease vary, depending on the phase of disease progression through ischemia, revascularization, fracture and collapse, and repair and remodeling of the bone. & Defects in COL2A1 are the cause of Kniest syndrome (KS) [MIM:156550]; also known as Kniest dysplasia or metatropic dwarfism type II. KS is a moderately severe chondrodysplasia phenotype that results from mutations in the COL2A1 gene. Characteristics of the disorder include a short trunk and extremities, mid-face hypoplasia, cleft palate, myopia, retinal detachment, and hearing loss. & Defects in COL2A1 are a cause of primary avascular necrosis of femoral head (ANFH) [MIM:608805]; also called ischemic necrosis of the femoral head or osteonecrosis of the femoral head. ANFH causes disability that often requires surgical intervention. Most cases are sporadic, but families in which there is an autosomal dominant inheritance of the disease have been identified. It has been estimated that 300,000 to 600,000 people in the United States have ANFH. Approximately 15,000 new cases of this common and disabling disorder are reported annually. The age at the onset is earlier than that for osteoarthritis. The diagnosis is typically made when patients are between the ages of 30 and 60 years. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. Moreover, nearly 10 percent of the 500,000 total-hip arthroplasties performed each year in the United States involve patients with ANFH. As a result, this disease creates a substantial socioeconomic cost as well as a burden for patients and their families. & Defects in COL2A1 are the cause of osteoarthritis with mild chondrodysplasia [MIM:604864]. Osteoarthritis is a common disease that produces joint pain and stiffness together with radiologic evidence of progressive degeneration of joint cartilage. Some forms of osteoarthritis are secondary to events such as trauma, infections, metabolic disorders, or congenital or heritable conditions that deform the epiphyses or related structures. In most patients, however, there is no readily identifiable cause of osteoarthritis. Inheritance in a Mendelian dominant manner has been demonstrated in some families with primary generalized osteoarthritis. Reports demonstrate coinheritance of primary generalized osteoarthritis with specific alleles of the gene COL2A1, the precursor of the major protein of cartilage. & Defects in COL2A1 are the cause of platyspondylic lethal skeletal dysplasia Torrance type (PLSD-T) [MIM:151210]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-T is characterized by varying platyspondyly, short ribs with anterior cupping, hypoplasia of the lower ilia with broad ischial and pubic bones, and shortening of the tubular bones with splayed and cupped metaphyses. Histology of the growth plate typically shows focal hypercellularity with slightly enlarged chondrocytes in the resting cartilage and relatively well-preserved columnar formation and ossification at the chondro-osseous junction. PLSD-T is generally a perinatally lethal disease, but a few long-term survivors have been reported. & Defects in COL2A1 are the cause of multiple epiphyseal dysplasia with myopia and conductive deafness (EDMMD) [MIM:132450]. Multiple epiphyseal dysplasia is a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. EDMMD is an autosomal dominant disorder characterized by epiphyseal dysplasia associated with progressive myopia, retinal thinning, crenated cataracts, conductive deafness. & Defects in COL2A1 are the cause of spondyloperipheral dysplasia (SPD) [MIM:271700]. SPD patients manifest short stature, midface hypoplasia, sensorineural hearing loss, spondyloepiphyseal dysplasia, platyspondyly and brachydactyly. & Defects in COL2A1 are the cause of Wagner syndrome type II (WS-II); a disease characterized by early-onset cataracts, lattice degeneration of the retina, and retinal detachment without involvement of monocular tissues. & Defects in COL2A1 are the cause of Stickler syndrome type 1 (STL1) [MIM:108300]; also known as vitreous type 1, or membranous vitreous type. STL1 is an autosomal dominant disorder characterized by progressive myopia beginning in the first decade of life, vitreo-retinal degeneration, retinal detachment, cleft palate, midfacial hypoplasia, osteoarthritis, and sensorineural hearing loss. & Defects in COL2A1 are a cause of autosomal dominant rhegmatogenous retinal detachment (DRRD) [MIM:609508]. RDD most frequently results from retinal tearing at the time of posterior vitreous detachment. Non-syndromic RRD can be inherited in a clearly dominant fashion, although in most of these cases, the genetic locus for the disorder is unknown. However, RRD is also a common feature of the type II collagenopathies (disorders due to mutations in the gene COL2A1) and some recent examples of mutations in this gene suggest that COL2A1 should be considered a candidate gene for dominant RRD (DRRD). & Of special interest are three different variants that replace arginine codons at positions 275, 719 and 989 in the triple-helical domain with codons for cysteine, an amino acid not normally found in the triple-helical domain of type II collagen from any species. They are of special interest, because they are the only amino acid substitutions in the triple-helical domain that replaces a Y-position amino acid and cause a disease phenotype. Also, they are recurrent in that they have been found in more than one unrelated individual.
      SIMILARITY: SwissProt: P02458 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain at 2-8°C for up to 12 months from date of reciept. Remove any nondispersed aggregates by microcentrifugation prior to use.
      Packaging Information
      Material Size500 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      AB761 04053252583216

      Documentation

      Required Licenses

      Title
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      Anti-Collagen Type II Antibody SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-Collagen Type II Antibody Certificates of Analysis

      TitleLot Number
      RABBIT ANTI-HUMAN COLLAGEN TYPE II 2483222
      RABBIT ANTI-HUMAN COLLAGEN TYPE II POLYCLONAL ANTIBODY - 2151814 2151814
      RABBIT ANTI-HUMAN COLLAGEN TYPE II POLYCLONAL ANTIBODY - 2428446 2428446
      RABBIT ANTI-HUMAN COLLAGEN TYPE II POLYCLONAL ANTIBODY - 2453117 2453117
      RABBIT ANTI-HUMAN COLLAGEN TYPE II POLYCLONAL ANTIBODY - 2151559 2151559
      RABBIT ANTI-HUMAN COLLAGEN TYPE II - 2492120 2492120
      RABBIT ANTI-HUMAN COLLAGEN TYPE II - 3191440 3191440
      RABBIT ANTI-HUMAN COLLAGEN TYPE II - 3229399 3229399
      RABBIT ANTI-HUMAN COLLAGEN TYPE II - 3378747 3378747
      RABBIT ANTI-HUMAN COLLAGEN TYPE II - 3464131 3464131

      References

      Reference overviewPub Med ID
      Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study.
      Naik, V; Leaf, EM; Hu, JH; Yang, HY; Nguyen, NB; Giachelli, CM; Speer, MY
      Cardiovascular research  94  545-54  2012

      Show Abstract
      22436847 22436847
      Vitalization of porous polyethylene (medpor(®)) with chondrocytes promotes early implant vascularization and incorporation into the host tissue.
      Susanne Ehrmantraut,Andreas Naumann,Vivienne Willnecker,Stephanie Akinyemi,Christina Körbel,Claudia Scheuer,Andrea Meyer-Lindenberg,Michael D Menger,Matthias W Laschke
      Tissue engineering. Part A  18  2012

      Show Abstract
      22452340 22452340
      Genipin cross-linked fibrin hydrogels for in vitro human articular cartilage tissue-engineered regeneration.
      Emma V Dare, May Griffith, Philippe Poitras, James A Kaupp, Stephen D Waldman, David J Carlsson, Geoffrey Dervin, Christine Mayoux, Maxwell T Hincke
      Cells, tissues, organs  190  313-25  2009

      Show Abstract
      19287127 19287127
      Discoidin domain receptor-1 deficiency attenuates atherosclerotic calcification and smooth muscle cell-mediated mineralization.
      Ahmad PJ, Trcka D, Xue S, Franco C, Speer MY, Giachelli CM, Bendeck MP
      The American journal of pathology  175  2686-96  2009

      Show Abstract
      19893047 19893047
      Participation of collagen types I, III, IV, V, and fibronectin in the formation of villi fibrosis in human term placenta.
      Rukosuev, V S, et al.
      Acta Histochem., 89: 11-6 (1990)  1990

      Show Abstract
      1705376 1705376
      Comparative analysis of collagens solubilized from human foetal, and normal and osteoarthritic adult articular cartilage, with emphasis on type VI collagen
      Ronziere, M. C. et al.
      Biochimica et Biophysica Acta, 1038:222-230 (1990)  1990

      2331486 2331486

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      AB746P Anti-Collagen Type II Antibody Show Pricing & Availability
      MAB1330 Anti-Collagen Type II Antibody, clone COLL-II Show Pricing & Availability
      MAB8887 Anti-Collagen Type II Antibody, clone 6B3 Show Pricing & Availability

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies